Dyne Therapeutics Inc (DYN)
24.98
-0.46
(-1.81%)
USD |
NASDAQ |
Apr 24, 16:00
24.99
+0.01
(+0.04%)
After-Hours: 20:00
Dyne Therapeutics Cash from Operations (TTM): -188.16M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -188.16M |
September 30, 2023 | -182.34M |
June 30, 2023 | -174.55M |
March 31, 2023 | -149.81M |
December 31, 2022 | -153.64M |
September 30, 2022 | -152.52M |
June 30, 2022 | -136.67M |
Date | Value |
---|---|
March 31, 2022 | -151.91M |
December 31, 2021 | -119.56M |
September 30, 2021 | -111.53M |
June 30, 2021 | -96.46M |
March 31, 2021 | -57.61M |
December 31, 2020 | -46.51M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-188.16M
Minimum
Dec 2023
-46.51M
Maximum
Dec 2020
-132.41M
Average
-149.81M
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
Rocket Pharmaceuticals Inc | -194.92M |
Solid Biosciences Inc | -94.18M |
Avidity Biosciences Inc | -119.06M |
Sana Biotechnology Inc | -253.58M |
Tenaya Therapeutics Inc | -102.07M |